These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35040698)

  • 1. CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
    Peterfy C; Chen Y; Countryman P; Chmielowski B; Anthony SP; Healey JH; Wainberg ZA; Cohn AL; Shapiro GI; Keedy VL; Singh A; Puzanov I; Wagner AJ; Qian M; Sterba M; Hsu HH; Tong-Starksen S; Tap WD
    Future Oncol; 2022 Apr; 18(12):1449-1459. PubMed ID: 35040698
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
    Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
    Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
    Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
    Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
    Tap WD; Gelderblom H; Palmerini E; Desai J; Bauer S; Blay JY; Alcindor T; Ganjoo K; Martín-Broto J; Ryan CW; Thomas DM; Peterfy C; Healey JH; van de Sande M; Gelhorn HL; Shuster DE; Wang Q; Yver A; Hsu HH; Lin PS; Tong-Starksen S; Stacchiotti S; Wagner AJ;
    Lancet; 2019 Aug; 394(10197):478-487. PubMed ID: 31229240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
    Gelderblom H; de Sande MV
    Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
    Gelderblom H; Razak AA; Taylor MH; Bauer TM; Wilky B; Martin-Broto J; Gonzalez AF; Rutkowski P; Szostakowski B; Alcindor T; Saleh R; Genta S; Stacchiotti S; van de Sande M; Wagner AJ; Bernthal N; Davis LE; Vuky J; Tait C; Matin B; Narasimhan S; Sharma MG; Ruiz-Soto R; Sherman ML; Tap WD
    Clin Cancer Res; 2024 Sep; 30(18):3996-4004. PubMed ID: 38995311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
    Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
    Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN.
    Healey JH; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; van de Sande M
    Clin Orthop Relat Res; 2023 Jan; 481(1):107-116. PubMed ID: 36001000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors.
    Thangaiah JJ; Koepplin JW; Folpe AL
    Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.
    Mastboom MJL; Lips W; van Langevelde K; Mifsud M; Ng C; McCarthy CL; Athanasou NA; Gibbons CLMH; van de Sande MAJ
    Surg Oncol; 2020 Dec; 35():261-267. PubMed ID: 32932224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 17. Tenosynovial giant cell tumor-diffuse type, treated with a novel colony-stimulating factor inhibitor, pexidartinib: initial experience with MRI findings in three patients.
    Helming A; Hansford B; Beckett B
    Skeletal Radiol; 2022 May; 51(5):1085-1091. PubMed ID: 34586485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
    Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
    Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature.
    Giustini N; Bernthal NM; Bukata SV; Singh AS
    Clin Sarcoma Res; 2018; 8():14. PubMed ID: 30002809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.